Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M2698 + trastuzumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
M2698 + trastuzumab is a combination therapy consisting of M2698, an orally available small molecule dual inhibitor of p70S6K and AKT (specifically Akt 1/3), and trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2). M2698 inhibits two key nodes in the PI3K/AKT/mTOR (PAM) pathway, which is implicated in tumor progression and resistance to therapy. Trastuzumab binds to HER2 receptors on cancer cells, inhibiting their proliferation. The combination has demonstrated antitumor activity in patients with advanced breast cancer resistant to multiple standard therapies and shows promise for overcoming treatment resistance. Preclinical studies also support its efficacy in HER2-positive gastric cancer models[1][2][3].
- Brand names
- HerceptinHerzumaKanjintiOgivriOntruzantTrazimeraHercessi
- Other names
- none
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)RPS6KB1 (Ribosomal protein S6 kinase beta-1)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on M2698 + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M2698 + trastuzumab.